Table 1.
Patient characteristics based on SSNHL type.
| Parameters | Successive bilateral SSNHL (n = 33) | Unilateral SSNHL (n = 215) |
|---|---|---|
| Age (years), mean ± SD | 48.67 ± 15.36∗ | 42.71 ± 13.58 |
| Age ≤ 42 years:>42 years, number | 9 : 24 | 114 : 101 |
| Males : females, number | 18 : 15 | 112 : 103 |
| NLR, mean ± SD | 5.72 ± 2.23∗ | 4.45 ± 2.82 |
| NLR ≤ 3.91:>3.91, number | 4 : 29 | 111 : 104 |
| MLR, mean ± SD | 0.25±0.15∗∗ | 0.17 ± 0.11 |
| MLR ≤ 0.24:>0.24, number | 14 : 19 | 167 : 48 |
| PLR, mean ± SD | 190.70±69.79∗∗ | 148.18 ± 65.67 |
| PLR ≤ 166.59:>166.59, number | 12 : 21 | 148 : 67 |
| LDL (mmol/L), mean ± SD | 3.79 ± 0.53∗ | 3.49 ± 0.74 |
| LDL ≤ 3.52:>3.52, number | 9 : 24 | 146 : 69 |
| HDL (mmol/L), mean ± SD | 1.33 ± 0.32∗ | 1.44 ± 0.26 |
| HDL ≤ 1.42:>1.42, number | 23 : 10 | 77 : 138 |
| Total cholesterol (mmol/L), mean ± SD | 5.74 ± 0.63 | 5.78 ± 3.16 |
| Triglyceride (mmol/L), mean ± SD | 1.47 ± 0.56 | 1.40 ± 1.23 |
| Fibrinogen (g/L), mean ± SD | 4.03±0.47∗∗ | 3.70 ± 0.65 |
| Fibrinogen ≤ 4.25:>4.25, number | 18 : 15 | 170 : 45 |
| PT (sec), mean ± SD | 10.94 ± 0.82 | 11.51 ± 0.63 |
| APTT (sec), mean ± SD | 25.94 ± 2.55 | 26.44 ± 3.51 |
| Smoking, number (%) | 12 (36%) | 66 (31%) |
| Alcohol consumption, number (%) | 5 (15%) | 38 (18%) |
| Hypertension, number (%) | 8 (24%) | 42 (20%) |
| Diabetes, number (%) | 19 (57%)∗∗ | 67 (32%) |
| Statins, number (%) | 8 (24%) | 45 (21%) |
| Antihypertensive therapy, number (%) | 7 (21%) | 40 (19%) |
| Nitrates | 0 (0%) | 0 (0%) |
| Angiotensin-converting enzyme inhibitors | 2 (6%) | 10 (5%) |
| Beta blockers | 1 (3%) | 5 (2%) |
| Angiotensin receptor blockers | 2 (6%) | 10 (5%) |
| Calcium channel blockers | 2 (6%) | 15 (7%) |
| Accompanying symptoms, number (%) | ||
| Dizziness | 12 (36%) | 71 (33%) |
| Tinnitus | 23 (70%) | 146 (68%) |
| Ear fullness | 18 (55%) | 112 (52%) |
| Total effective rate, number (%) | 4 (12%)∗∗ | 126 (59%) |
∗ p < 0.05, ∗∗p < 0.01, vs. unilateral SSNHL; SSNHL: sudden sensorineural hearing loss; NLR: neutrophil lymphocyte ratio; PLR: platelet lymphocyte ratio; MLR: monocyte lymphocyte ratio; LDL: low-density lipoprotein; HDL: high-density lipoprotein; PT: prothrombin time; APTT: activated partial thromboplastin time.